Gamida Cell Ltd (GMDAQ)

[midastouch017]

Gamida Cell Ltd. (NASDAQ:GMDA)
Number of Hedge Fund Holders: 12

Decline in Share Price in 2021: 75.8%

Like most other stocks in the ARK portfolio, Gamida Cell Ltd. (NASDAQ:GMDA), a clinical-stage biotech firm developing therapies for cancer and blood diseases, has not had positive hedge fund coverage in the second half of 2021. At the end of the third quarter of 2021, 12 hedge funds in the database of Insider Monkey held stakes worth $26 million in Gamida Cell Ltd. (NASDAQ:GMDA), compared to 14 the preceding quarter worth $53 million.

ARK first bought a stake in Gamida Cell Ltd. (NASDAQ:GMDA) in the third quarter of 2020, buying over 186,000 shares at an average price of $4.26 per share. The fund then added to that position substantially in the next three quarters, by 72%, 108%, and 2% respectively, before slashing it by over 9% between June and September 2021. It now owns 623,674 shares in Gamida Cell Ltd. (NASDAQ:GMDA) worth $2.4 million.

https://finance.yahoo.com/news/15-worst-stock-picks-cathie-163728887.html